Glutethimide scheduling
Executive Summary
The Drug Enforcement Administration proposes to transfer glutethimide from Schedule III to Schedule II of the Controlled Substances Act in a July 26 Federal Register notice. The action is based on evidence of abuse and diversion of the drug and on the recommendation of the Assistant Secretary for Health. Comments must be submitted by Sept. 24. FDA's Drug Abuse Advisory Committee recommended that the hypnotic sedative be moved to Schedule II ("The Pink Sheet" June 11, T&G-4). A number of generic firms manufacture the drug.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.